Scientists at Harvard Medical School confirmed in a mouse model that combining an HDAC2 inhibitor with a PD-1 (programmed cell death protein 1) antibody significantly suppresses tumor growth and improves survival rates, suggesting that HDAC2 might be a new potential option for combination therapy with PD-1 inhibitors.155. Here, HDAC2 is linked to neoplasm.